Quote Request
Metabolomics Analysis for Pancreatic Cancer
Due to the complex and latent pathogenesis of pancreatic cancer and the lack of early diagnostic methods, pancreatic cancer is one of the most aggressive and lethal tumors among malignant tumors. Alfa Cytology's goal is to help our clients develop reliable biomarkers for the evaluation and management of pancreatic cancer. Here, we employ newly developed metabolomics methods to help our customers develop cancer metabolites for pancreatic cancer diagnostics, involving the identification and validation of metabolite biomarkers from various body fluids.
Overview of Metabolomics in Pancreatic Cancer
Metabolomics is defined as a holistic analytical approach to detecting low-molecular-weight metabolites in an organism or cell system. Metabolomics can be used to analyze a large number of compounds and biological samples for cancer screening and early detection. This method involves obtaining tissues or using less invasive methods such as collecting serum, saliva, urine, and other biofluids. Cancer is known to have altered cellular metabolism. Gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR), and liquid chromatography (LC)-MS are sensitive and commonly used techniques to determine subtle chemical changes caused by metabolic disturbances during tumor development.
Fig. 1 The metabolic rewiring of cancer cells during metastasis. (Nascentes LM., et al., 2022)
Pancreatic cancer is characterized by significant metabolic reprogramming, which supports the aggressive growth and survival of tumor cells. Metabolomics helps in elucidating how these metabolic changes drive tumor progression, allowing researchers to pinpoint key metabolic pathways involved in cancer development.
One of the primary applications of metabolomics is the identification of biomarkers—metabolites whose levels change significantly in response to disease. These biomarkers can be used for early detection of pancreatic cancer, assessment of disease stage, and monitoring of treatment efficacy.
By mapping the altered metabolic pathways in pancreatic cancer cells, metabolomics facilitates the discovery of potential therapeutic targets. This information can guide the development of novel drugs that specifically disrupt tumor metabolism, potentially leading to more effective treatments.
Key Metabolic Changes in Pancreatic Cancer
Glucose Metabolism
Amino Acid Metabolism
Lipid Metabolism
Oxidative Stress
Pancreatic cancer cells often exhibit increased glycolysis and altered glucose metabolism, contributing to tumor growth and resistance to therapy.
Changes in amino acid levels and pathways are commonly observed in pancreatic cancer, impacting protein synthesis and cell signaling.
Altered lipid metabolism is linked to cancer cell proliferation, membrane synthesis, and resistance to apoptosis.
Metabolic changes in oxidative stress and antioxidant defense mechanisms are crucial for understanding pancreatic cancer progression and response to treatment.
Our Services
Alfa Cytology offers a comprehensive range of metabolomics services tailored to pancreatic cancer research.
Metabolite Biomarker Discover
Identifying novel biomarkers for early detection, prognosis, and treatment monitoring through comprehensive metabolite profiling.
Metabolic Pathway Analysis
Investigating specific metabolic pathways altered in pancreatic cancer to uncover potential therapeutic targets.
By Tissue Type
We accept various tissue samples for metabolomics analysis aimed at identifying potential biomarkers for pancreatic cancer. The categories and corresponding biomarkers are as follows:
| Types | Biomarkers |
| Pancreatic Tissue | Leucine, isoleucine, valine, lactate, alanine, phosphocholine, glycerophosphocholine, taurine, and betaine; as well as taurine, lactate, creatine, and glutamate. |
| Serum | 3-hydroxybutyrate, 3-hydroxy isovalerate, lactate, trimethylamine-N-oxide, isoleucine, triglyceride, leucine, and creatine; along with glutamate, acetone, glucose, phenylalanine, formate, mannose, ethanol, asparagine, creatine, proline, and glycerol. |
| Plasma | N-methyl alanine, lysine, glutamine, phenylalanine, arachidonic acid, lysophosphatidylcholine (18:2), phosphatidylcholine (34:2), phosphatidylethanolamine (26:0), tauroursodeoxycholic acid, taurocholic acid, deoxycholylglycine, and cholylglycine. |
| Urine | Acetoacetate, citrate, creatinine, glucose, glycine, hippurate, 3-hydroxyisovalerate, leucine, 2-phenylacetamide, and trigonelline. |
| Saliva | Leucine, isoleucine, tryptophan, valine, glutamate, phenylalanine, glutamine, and aspartate. |
Why Choose Us?
Scientific Experience
Professional team of scientists and more than ten years of experience in pancreatic cancer
Customized Service
Tailored services dedicated to ensuring customer satisfaction
Data Security
Strictly keep confidential the client's project information and experimental data
Quick Reply
Our customer service representatives are available 24 hours a day from Monday to Sunday
The ideal diagnostic biomarkers for effective screening are those that can be obtained in a minimally invasive manner and that can distinguish pancreatic cancer from healthy individuals or other benign pancreatic diseases with satisfactory sensitivity and specificity. If you are interested in learning more about our pancreatic cancer vaccine development services, would like to learn more about our services and opportunities to participate in market research, or are interested in a potential partnership or collaboration, please don't hesitate to contact us. Our professional and patient staff will contact you as soon as possible.
Reference
- Nascentes Melo LM, Lesner NP, Sabatier M, Ubellacker JM, Tasdogan A. Emerging metabolomic tools to study cancer metastasis. Trends Cancer. 2022 Dec;8(12):988-1001.
